All In Biotech

Drug Trial Radar · NCT01222247

Antenatal Late Preterm Steroids (ALPS): A Randomized Placebo-Controlled Trial

Last checked: Nov 19, 2026Latest source record: Mar 28, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 2,831 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

2,831

Actual

Start

Oct 2010

Primary completion

Mar 2015

Study completion Aug 31, 2022

Sponsor

Lead sponsor
The George Washington University Biostatistics CenterAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
National Heart, Lung, and Blood Institute (NHLBI); Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
First posted
Oct 18, 2010

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Prevention
FDA-regulated drug
Yes
Who can join
Female only
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This is a randomized placebo controlled trial to evaluate whether antenatal corticosteroids can decrease the rate of neonatal respiratory support, thus decreasing the rate of NICU admissions and improving short-term outcomes in the late preterm infant. The use of antenatal corticosteroids has been shown to be beneficial in women at risk for preterm delivery prior to 34 weeks but has not been evaluated in those likely to deliver in the late preterm period

Conditions

  • Pregnancy
  • Respiratory Distress Syndrome
  • Pregnancy Outcomes
  • Preterm Birth

Interventions

  • BetamethasoneDrug

    The active study drug, betamethasone. 3 mg per ml betamethasone sodium phosphate 3 mg per milliliter betamethasone acetate The first dose of study drug medication will be administered at randomization as 2 ml injection; the next dose of 2 ml will be administered 24 hours later.

  • PlaceboDrug

    Similar course of identical appearing placebo: 2 mL IM injections, 24 hours apart.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Neonatal Composite OutcomeTime frame: 72 hours of life

Locations

17 sites in 1 country. Site status is shown where the registry gives one.

  • University of Alabama - Birmingham

    Birmingham, Alabama

  • Stanford University

    Stanford, California

  • University of Colorado

    Denver, Colorado

  • Northwestern University

    Chicago, Illinois

  • Wayne State University

    Detroit, Michigan

  • Columbia University

    New York, New York

  • University of North Carolina - Chapel Hill

    Chapel Hill, North Carolina

  • Duke University

    Durham, North Carolina

  • Case Western Reserve University

    Cleveland, Ohio

  • Ohio State University

    Columbus, Ohio

  • Oregon Health & Science University

    Portland, Oregon

  • University of Pittsburgh Magee Womens Hospital

    Pittsburgh, Pennsylvania

  • Brown University

    Providence, Rhode Island

  • University of Texas - Southwest

    Dallas, Texas

  • University of Texas - Galveston

    Galveston, Texas

  • University of Texas - Houston

    Houston, Texas

  • University of Utah Medical Center

    Salt Lake City, Utah

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.